Physiological and pathophysiological roles of NAMPT and NAD metabolism

[1]  M. Hosseinzadeh‐Attar,et al.  The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. , 2015, Diabetes & metabolic syndrome.

[2]  K. Tobe,et al.  SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice. , 2015, Cell metabolism.

[3]  R. Gebhardt,et al.  FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. , 2015, Biochemical and biophysical research communications.

[4]  D. Rossi,et al.  Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. , 2015, Blood.

[5]  E. Wagner,et al.  Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. , 2014, Cancer cell.

[6]  A. S. Al-Goblan,et al.  Mechanism linking diabetes mellitus and obesity , 2014, Diabetes, metabolic syndrome and obesity : targets and therapy.

[7]  G. Magni,et al.  Metabolic Profiling of Alternative NAD Biosynthetic Routes in Mouse Tissues , 2014, PloS one.

[8]  J. Baur,et al.  Increasing NAD Synthesis in Muscle via Nicotinamide Phosphoribosyltransferase Is Not Sufficient to Promote Oxidative Metabolism* , 2014, The Journal of Biological Chemistry.

[9]  F. Mazzola,et al.  Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD+ biosynthetic machinery in mammalian cells , 2014, The FEBS journal.

[10]  J. Chudek,et al.  Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population - results from the PolSenior substudy. , 2014, Metabolism: clinical and experimental.

[11]  A. Roulston,et al.  Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. , 2014, Cancer research.

[12]  A. Ballestrero,et al.  Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity* , 2014, The Journal of Biological Chemistry.

[13]  R. Leak,et al.  Neuronal NAMPT is Released after Cerebral Ischemia and Protects against White Matter Injury , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  F. Joseph,et al.  Adipose Tissue and Adipokines: The Association with and Application of Adipokines in Obesity , 2014, Scientifica.

[15]  E. Knoll,et al.  Mechanism of Inhibition of the Human Sirtuin Enzyme SIRT3 by Nicotinamide: Computational and Experimental Studies , 2014, PloS one.

[16]  Dong-Mei Wu,et al.  Troxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice. , 2014, Biochemical pharmacology.

[17]  A. Poeppl,et al.  On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells , 2014, Clinical Cancer Research.

[18]  T. Zhou,et al.  Expression of Nicotinamide Phosphoribosyltransferase-Influenced Genes Predicts Recurrence-Free Survival in Lung and Breast Cancers , 2014, Scientific Reports.

[19]  T. Romacho,et al.  Visfatin/Nampt induces telomere damage and senescence in human endothelial cells. , 2014, International journal of cardiology.

[20]  L. Guarente,et al.  NAD+ and sirtuins in aging and disease. , 2014, Trends in cell biology.

[21]  M. K. MotawiTarek,et al.  Visfatin −948G/T and resistin −420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases , 2014 .

[22]  S. Imai,et al.  Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging , 2014, The EMBO journal.

[23]  H. Wee,et al.  Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer , 2014, Oncotarget.

[24]  D. Kim,et al.  Extracellular Visfatin Activates Gluconeogenesis in HepG2 Cells Through the Classical PKA/CREB-Dependent Pathway , 2014, Hormone and Metabolic Research.

[25]  R. Gebhardt,et al.  Resveratrol Differentially Regulates NAMPT and SIRT1 in Hepatocarcinoma Cells and Primary Human Hepatocytes , 2014, PloS one.

[26]  L. Guarente,et al.  SIRT1 and other sirtuins in metabolism , 2014, Trends in Endocrinology & Metabolism.

[27]  Young‐Hee Kang,et al.  Blockade of visfatin induction by oleanolic acid via disturbing IL-6-TRAF6-NF-κB signaling of adipocytes , 2014, Experimental biology and medicine.

[28]  M. Blüher.  Adipokines – removing road blocks to obesity and diabetes therapy☆ , 2014, Molecular metabolism.

[29]  Won-Young Lee,et al.  Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes. , 2014, The Journal of nutritional biochemistry.

[30]  Pei-Hsi Wang,et al.  Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[31]  P. Zhang,et al.  Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group , 2014, Tumor Biology.

[32]  B. Zhao,et al.  Cerebral Ischemia Is Exacerbated by Extracellular Nicotinamide Phosphoribosyltransferase via a Non-Enzymatic Mechanism , 2013, PloS one.

[33]  Xiaoling Li,et al.  Elevated microRNA‐34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT , 2013, Aging cell.

[34]  A. Bürkle,et al.  Poly(ADP-ribose): PARadigms and PARadoxes. , 2013, Molecular aspects of medicine.

[35]  M. Ziegler,et al.  NAD biosynthesis in humans--enzymes, metabolites and therapeutic aspects. , 2013, Current topics in medicinal chemistry.

[36]  Shuiping Zhao,et al.  Ox-LDL Induces ER Stress and Promotes the adipokines Secretion in 3T3-L1 Adipocytes , 2013, PloS one.

[37]  M. Sehested,et al.  Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. , 2013, Journal of medicinal chemistry.

[38]  A. Jaleel,et al.  Association of adipokines with obesity in children and adolescents. , 2013, Biomarkers in medicine.

[39]  J. Vieira,et al.  Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects , 2013, Cardiovascular Diabetology.

[40]  M. D. di Girolamo,et al.  A role of intracellular mono‐ADP‐ribosylation in cancer biology , 2013, The FEBS journal.

[41]  L. Sturla,et al.  CD73 Protein as a Source of Extracellular Precursors for Sustained NAD+ Biosynthesis in FK866-treated Tumor Cells* , 2013, The Journal of Biological Chemistry.

[42]  J. Auwerx,et al.  NAD+ metabolism: A therapeutic target for age-related metabolic disease , 2013, Critical reviews in biochemistry and molecular biology.

[43]  S. Bağcı,et al.  Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. , 2013, Annals of hepatology.

[44]  T. Romacho,et al.  Visfatin/Nampt: An Adipokine with Cardiovascular Impact , 2013, Mediators of inflammation.

[45]  G. Tarantino,et al.  What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? , 2013, World journal of gastroenterology.

[46]  T. Rohan,et al.  Visfatin, a potential biomarker and prognostic factor for endometrial cancer. , 2013, Gynecologic oncology.

[47]  A. Massarotti,et al.  Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. , 2013, Journal of medicinal chemistry.

[48]  R. Buijs,et al.  Shift Work or Food Intake during the Rest Phase Promotes Metabolic Disruption and Desynchrony of Liver Genes in Male Rats , 2013, PloS one.

[49]  M. Scholz,et al.  Seminal plasma adipokine levels are correlated with functional characteristics of spermatozoa. , 2013, Fertility and sterility.

[50]  M. Hosseinzadeh‐Attar,et al.  Effect of Weight Reduction Following Bariatric Surgery on Serum Visfatin and Adiponectin Levels in Morbidly Obese Subjects , 2013, Obesity Facts.

[51]  S. Ye,et al.  Expression and Regulation of Nampt in Human Islets , 2013, PloS one.

[52]  V. Schramm,et al.  Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase. , 2013, Journal of the American Chemical Society.

[53]  C. Richart,et al.  Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. , 2013, Clinical biochemistry.

[54]  Gene Kim,et al.  Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. , 2013, American journal of physiology. Heart and circulatory physiology.

[55]  M. Kukla,et al.  Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. , 2013, Oncology reports.

[56]  M. Engelse,et al.  The Adipocytokine Nampt and Its Product NMN Have No Effect on Beta-Cell Survival but Potentiate Glucose Stimulated Insulin Secretion , 2013, PloS one.

[57]  D. Reinhardt,et al.  Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells , 2012, International journal of cancer.

[58]  K. Cianflone,et al.  Elevated visfatin levels in obese children are related to proinflammatory factors , 2012, Journal of pediatric endocrinology & metabolism : JPEM.

[59]  H. Cortez‐Pinto,et al.  miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. , 2013, Journal of hepatology.

[60]  Tao Wang,et al.  Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells , 2012, The Journal of Biological Chemistry.

[61]  Jiyeon Lee,et al.  Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. , 2012, American journal of physiology. Endocrinology and metabolism.

[62]  C. Richart,et al.  Increased levels and adipose tissue expression of visfatin in morbidly obese women: the relationship with pro‐inflammatory cytokines , 2012, Clinical endocrinology.

[63]  M. Ziegler,et al.  The NAD metabolome — a key determinant of cancer cell biology , 2012, Nature Reviews Cancer.

[64]  N. Munshi,et al.  Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. , 2012, Blood.

[65]  S. Kridel,et al.  Nicotinamide Phosphoribosyl Transferase (Nampt) Is Required for De Novo Lipogenesis in Tumor Cells , 2012, PloS one.

[66]  J. Auwerx,et al.  The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. , 2012, Cell metabolism.

[67]  B. Kırel,et al.  Serum Visfatin Levels, Adiposity and Glucose Metabolism in Obese Adolescents , 2012, Journal of clinical research in pediatric endocrinology.

[68]  Jana Husse,et al.  Circadian Desynchrony Promotes Metabolic Disruption in a Mouse Model of Shiftwork , 2012, PloS one.

[69]  S. Grzesiek,et al.  Monocytes Contribute to Differential Immune Pressure on R5 versus X4 HIV through the Adipocytokine Visfatin/NAMPT , 2012, PloS one.

[70]  M. Vacca,et al.  Effects of visfatin/PBEF/NAMPT on feeding behaviour and hypothalamic neuromodulators in the rat. , 2012, Journal of biological regulators and homeostatic agents.

[71]  W. Kraus,et al.  On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. , 2012, Genes & development.

[72]  F. Calegari,et al.  Age-related cognitive decline: Can neural stem cells help us? , 2012, Aging.

[73]  S. Hauschildt,et al.  Extracellular ATP induces P2X7-dependent nicotinamide phosphoribosyltransferase release in LPS-activated human monocytes , 2012, Innate immunity.

[74]  J. Bollerslev,et al.  Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. , 2012, The Journal of clinical endocrinology and metabolism.

[75]  J. Born,et al.  Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism. , 2012, The Journal of clinical endocrinology and metabolism.

[76]  S. Köklü,et al.  Visfatin Levels in Nonalcoholic Fatty Liver Disease , 2012, Journal of clinical laboratory analysis.

[77]  G. Askari,et al.  Lipid Profiles and Serum Visfatin Concentrations in Patients with Type II Diabetes in Comparison with Healthy Controls , 2012, International journal of preventive medicine.

[78]  L. Sturla,et al.  The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism. , 2012, The Biochemical journal.

[79]  Yup Kang,et al.  Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes. , 2011, Metabolism: Clinical and Experimental.

[80]  M. Krzystek-Korpacka,et al.  Visfatin in juvenile obesity – the effect of obesity intervention and sex , 2011, European journal of clinical investigation.

[81]  Wei Zhao,et al.  Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. , 2011, Oncology reports.

[82]  S. Bae,et al.  Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway , 2011, Neuroscience Letters.

[83]  S. Imai,et al.  Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. , 2011, Cell metabolism.

[84]  J. Argente,et al.  Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism , 2011, International Journal of Obesity.

[85]  M. Shimizu,et al.  Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells , 2011, Cancer Prevention Research.

[86]  J. Kieswich,et al.  Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function , 2011, Diabetologia.

[87]  Yu-Hung Chang,et al.  Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review , 2011, Diabetes/metabolism research and reviews.

[88]  H. Osago,et al.  Nicotinamide Phosphoribosyltransferase/Visfatin Does Not Catalyze Nicotinamide Mononucleotide Formation in Blood Plasma , 2011, PloS one.

[89]  D. Friebe,et al.  Impact of Metabolic Regulators on the Expression of the Obesity Associated Genes FTO and NAMPT in Human Preadipocytes and Adipocytes , 2011, PloS one.

[90]  A. Nikiforov,et al.  Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells , 2011, The Journal of Biological Chemistry.

[91]  R. DePinho,et al.  Hepatic FoxOs Regulate Lipid Metabolism via Modulation of Expression of the Nicotinamide Phosphoribosyltransferase Gene* , 2011, The Journal of Biological Chemistry.

[92]  G. Frühbeck,et al.  Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[93]  Amir A. Gabr,et al.  Serum visfatin levels in a group of Egyptian obese individuals. , 2011, The Egyptian journal of immunology.

[94]  H. El-Mesallamy,et al.  Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. , 2011, Metabolism: clinical and experimental.

[95]  M. Stumvoll,et al.  Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans , 2011, Diabetologia.

[96]  M. Kukla,et al.  Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. , 2011, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[97]  M. Sehested,et al.  Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase , 2010, BMC Cancer.

[98]  S. Ding,et al.  Visfatin regulates genes related to lipid metabolism in porcine adipocytes. , 2010, Journal of animal science.

[99]  A. Lapucci,et al.  Inhibition of Nicotinamide Phosphoribosyltransferase , 2010, Journal of Biological Chemistry.

[100]  M. Fasshauer,et al.  Visfatin Is a Positive Regulator of MCP‐1 in Human Adipocytes In Vitro and in Mice In Vivo , 2010, Obesity.

[101]  M. Rauh,et al.  Expression of Neuropeptide Y, Omentin and Visfatin in Visceral and Subcutaneous Adipose Tissues in Humans: Relation to Endocrine and Clinical Parameters , 2010, Obesity Facts.

[102]  M. Sasikala,et al.  Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. , 2010, Annals of hepatology.

[103]  P. Paschou,et al.  Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population. , 2010, Cytokine.

[104]  K. Birkeland,et al.  Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. , 2010, The Journal of clinical endocrinology and metabolism.

[105]  H. Tilg,et al.  Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. , 2010, Current pharmaceutical design.

[106]  E. Sarandol,et al.  Body fat distribution has no effect on serum visfatin levels in healthy female subjects. , 2010, Cytokine.

[107]  A. Kaminska,et al.  An evaluation of visfatin levels in obese subjects. , 2010, Endokrynologia Polska.

[108]  G. Gores,et al.  Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. , 2010, The Journal of clinical investigation.

[109]  M. Atalay,et al.  Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats , 2010, Mechanisms of Ageing and Development.

[110]  R. Gebhardt,et al.  Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. , 2010, Biochemical and biophysical research communications.

[111]  T. Church,et al.  Skeletal muscle NAMPT is induced by exercise in humans. , 2010, American journal of physiology. Endocrinology and metabolism.

[112]  R. Larsson,et al.  Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data , 2010, Cancer Chemotherapy and Pharmacology.

[113]  A. Ballestrero,et al.  Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE , 2009, PloS one.

[114]  A. Gürlek,et al.  Role of adipocytokines in predicting the development of diabetes and its late complications , 2009, Endocrine.

[115]  L. Rodríguez-Mañas,et al.  Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity , 2009, Diabetologia.

[116]  B. Balkau,et al.  A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity , 2009, Obesity.

[117]  S. Eom,et al.  Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor , 2009, Molecules and cells.

[118]  A. Ballestrero,et al.  APO866 activity in hematologic malignancies: a preclinical in vitro study. , 2009, Blood.

[119]  A. Chiarugi,et al.  Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. , 2009, Biochemical pharmacology.

[120]  P. Sassone-Corsi,et al.  Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1 , 2009, Science.

[121]  J. Takahashi,et al.  Circadian Clock Feedback Cycle Through NAMPT-Mediated NAD+ Biosynthesis , 2009, Science.

[122]  P. Greaney,et al.  The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. , 2009, Blood.

[123]  Wieland Kiess,et al.  Nampt: linking NAD biology, metabolism and cancer , 2009, Trends in Endocrinology & Metabolism.

[124]  H. Randeva,et al.  Relationship Between Cerebrospinal Fluid Visfatin (PBEF/Nampt) Levels and Adiposity in Humans , 2009, Diabetes.

[125]  H. Wee,et al.  Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. , 2009, Biochemical and biophysical research communications.

[126]  Véronique Kruys,et al.  Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner , 2009, Nature Medicine.

[127]  W. Kiess,et al.  Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. , 2009, Frontiers in bioscience.

[128]  O. Izaola,et al.  Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease , 2009, Digestive Diseases and Sciences.

[129]  Yuan Zhang,et al.  Extracellular Nampt Promotes Macrophage Survival via a Nonenzymatic Interleukin-6/STAT3 Signaling Mechanism* , 2008, Journal of Biological Chemistry.

[130]  Hyoung-Kyu kim,et al.  Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. , 2008, American journal of physiology. Renal physiology.

[131]  V. Schramm,et al.  Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. , 2008, Biochemistry.

[132]  Peter Stenvinkel,et al.  Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[133]  P. Kondaiah,et al.  PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value , 2008, Cancer biology & therapy.

[134]  H. Randeva,et al.  Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. , 2008, Cardiovascular research.

[135]  M. Sehested,et al.  Anticancer agent CHS-828 inhibits cellular synthesis of NAD. , 2008, Biochemical and biophysical research communications.

[136]  S. Imai,et al.  Age‐associated loss of Sirt1‐mediated enhancement of glucose‐stimulated insulin secretion in beta cell‐specific Sirt1‐overexpressing (BESTO) mice , 2008, Aging cell.

[137]  D. Denbow,et al.  Central visfatin causes orexigenic effects in chicks , 2008, Behavioural Brain Research.

[138]  P. Puigserver,et al.  Metabolic adaptations through the PGC‐1α and SIRT1 pathways , 2008 .

[139]  L. Saltz,et al.  The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor , 2008, Investigational New Drugs.

[140]  M. Blüher,et al.  Molecular characteristics of serum visfatin and differential detection by immunoassays. , 2007, The Journal of clinical endocrinology and metabolism.

[141]  J. Milbrandt,et al.  Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. , 2007, Cell metabolism.

[142]  Adriano Fontana,et al.  TNF-α suppresses the expression of clock genes by interfering with E-box-mediated transcription , 2007, Proceedings of the National Academy of Sciences.

[143]  M. Matsuda,et al.  Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. , 2007, Biochemical and biophysical research communications.

[144]  M. Stumvoll,et al.  Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. , 2007, Metabolism: clinical and experimental.

[145]  Kyu-Won Kim,et al.  Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. , 2007, Biochemical and biophysical research communications.

[146]  Yuji Kobayashi,et al.  Crystallization of human nicotinamide phosphoribosyltransferase. , 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

[147]  S. Cregan,et al.  Extension of Human Cell Lifespan by Nicotinamide Phosphoribosyltransferase* , 2007, Journal of Biological Chemistry.

[148]  H. Fried.  Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival , 2007 .

[149]  G. Deuretzbacher,et al.  TNF-α Alters Visfatin and Adiponectin Levels in Human Fat , 2007 .

[150]  Bounleut Phanavanh,et al.  Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. , 2007, The Journal of clinical endocrinology and metabolism.

[151]  Zi-qiang Luo,et al.  Insulin-Like Effects of Visfatin on Human Osteoblasts , 2007, Calcified Tissue International.

[152]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[153]  M. Matsuda,et al.  Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. , 2006, Biochemical and biophysical research communications.

[154]  J. Fernández-Real,et al.  Serum Visfatin Increases With Progressive β-Cell Deterioration , 2006, Diabetes.

[155]  S. Eom,et al.  Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. , 2006, Journal of molecular biology.

[156]  M. Luo,et al.  The visfatin gene is associated with glucose and lipid metabolism in a Chinese population , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[157]  M. Yoo,et al.  Hypoxic induction of human visfatin gene is directly mediated by hypoxia‐inducible factor‐1 , 2006, FEBS letters.

[158]  M. Stumvoll,et al.  Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. , 2006, The Journal of clinical endocrinology and metabolism.

[159]  C. Fielding,et al.  Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[160]  C. Wolberger,et al.  Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme , 2006, Nature Structural &Molecular Biology.

[161]  M. Wolzt,et al.  The release of the adipocytokine visfatin is regulated by glucose and insulin , 2006, Diabetologia.

[162]  M. Wolzt,et al.  Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. , 2006, The Journal of clinical endocrinology and metabolism.

[163]  R. Busse,et al.  Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin , 2006, Diabetologia.

[164]  Madeleine Lemieux,et al.  Sirt1 Regulates Insulin Secretion by Repressing UCP2 in Pancreatic β Cells , 2005, PLoS biology.

[165]  J. Khan,et al.  Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents , 2006, Nature Structural &Molecular Biology.

[166]  Shyi-Jang Shin,et al.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. , 2006, The Journal of clinical endocrinology and metabolism.

[167]  S. Imai,et al.  Poly(ADP-ribose) Polymerase-1-dependent Cardiac Myocyte Cell Death during Heart Failure Is Mediated by NAD+ Depletion and Reduced Sir2α Deacetylase Activity* , 2005, Journal of Biological Chemistry.

[168]  R. Paschke,et al.  Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. , 2005, American journal of physiology. Endocrinology and metabolism.

[169]  M. Matsuda,et al.  Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. , 2005, Science.

[170]  R. Paschke,et al.  Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. , 2005, The Journal of endocrinology.

[171]  H. Lodish,et al.  Visfatin: A New Adipokine , 2005, Science.

[172]  H. Lodish,et al.  Medicine. Visfatin: a new adipokine. , 2005, Science.

[173]  S. Imai,et al.  The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells* , 2004, Journal of Biological Chemistry.

[174]  R. Medema,et al.  FOXO4 Is Acetylated upon Peroxide Stress and Deacetylated by the Longevity Protein hSir2SIRT1* , 2004, Journal of Biological Chemistry.

[175]  C. Brenner,et al.  Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans , 2004, Cell.

[176]  Max Hasmann,et al.  FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. , 2003, Cancer research.

[177]  H. Fujisawa,et al.  Growth phase‐dependent changes in the subcellular localization of pre‐B‐cell colony‐enhancing factor 1 , 2003, FEBS letters.

[178]  D. Sinclair,et al.  Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1* , 2002, The Journal of Biological Chemistry.

[179]  D. Gigot,et al.  Pre‐B‐cell colony‐enhancing factor, whose expression is up‐regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis , 2002, European journal of immunology.

[180]  S. Ognjanovic,et al.  Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. , 2002, American journal of obstetrics and gynecology.

[181]  A. Knutsson,et al.  Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27 485 people , 2001, Occupational and environmental medicine.

[182]  R. Shea,et al.  Identification of a Plasmid-Encoded Gene fromHaemophilus ducreyi Which Confers NAD Independence , 2001, Journal of bacteriology.

[183]  C. Franceschi,et al.  Inflamm‐aging: An Evolutionary Perspective on Immunosenescence , 2000 .

[184]  I McNiece,et al.  Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor , 1994, Molecular and cellular biology.

[185]  Hon Cheung Lee,et al.  ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite. , 1991, Cell regulation.

[186]  Y. Yokoyama,et al.  Purification and characterization of poly (ADP-ribose) synthetase from human placenta. , 1987, The Journal of biological chemistry.

[187]  S. Chaykin,et al.  The management of nicotinamide and nicotinic acid in the mouse. , 1972, The Journal of biological chemistry.

[188]  P. Handler,et al.  Enzymatic synthesis of nicotinamide mononucleotide. , 1957, The Journal of biological chemistry.

[189]  D. Burk,et al.  On respiratory impairment in cancer cells. , 1956, Science.